Global Landscape Of Advanced Therapies In 2022

More than one in six drugs in development today are based upon sophisticated gene, cell or RNA modalities. The continued development of genetic technologies gives rise to a broad and diverse pipeline, pioneered by biotechs, encompassing a range of novel drug platforms. The proliferation of advanced therapies is pioneered by biotechs that specialize in a particular technology. Large pharmaceutical companies selectively add the most promising candidates to their pipelines, sourced from a range of companies and modalities.